2m 2m 2m 2m 2m 2m 2m
BOUNDLESS BIO (BOLD)
NASDAQ
$2.68+$0.08 (+3.08%)
Price as of Jun 23, 2026 7:59 PM EDT- $31.4MMarket Cap
- 140.74%1-Year Change
- BiotechnologyIndustry
BOUNDLESS BIO (BOLD)
$2.68+$0.08 (+3.08%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | |
Research and Development Expense | -44.8M -18.86% | -55.3M N/A | |
Depreciation and Amortization Expense | 1.3M +15.19% | 1.1M N/A | |
Total Operating Expenses | 63.6M -13.26% | 73.3M N/A | |
Operating Profit | -63.6M -13.26% | -73.3M N/A | |
Interest Income | 5.4M -32.12% | 7.9M N/A | |
Interest Expense | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 5.4M -32.12% | 7.9M N/A | |
Total Nonoperating Income and Expense | 5.4M -32.25% | 7.9M N/A | |
Income before Taxes | -63.6M -13.26% | -73.3M N/A | |
Income Taxes | 0 N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | -58.2M -10.96% | -65.4M N/A | |
Net Income from Continuing Operations Applicable to Common | -58.2M -10.96% | -65.4M N/A | |
Basic EPS and Net Income | -2.60 -32.47% | -3.85 N/A | |
Diluted EPS and Net Income | -2.60 -32.47% | -3.85 N/A | |
Basic Weighted Average Shares | 22.4M +31.65% | 17.0M N/A | |
Diluted Weighted Average Shares | 22.4M +31.65% | 17.0M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 17.9M -32.79% | 26.6M N/A | |
Short-Term Investments | 89.7M -28.53% | 125.5M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 107.6M -29.28% | 152.1M N/A | |
Total Current Assets | 109.6M -29.00% | 154.4M N/A | |
Accumulated Depreciation | 5.0M +33.73% | 3.7M N/A | |
Property and Plant and Equipment and Net | 3.2M -25.57% | 4.3M N/A | |
Total Long-Term Assets | 13,000 -86.87% | 99,000 N/A | |
Total Assets | 157.1M -23.91% | 206.4M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | |
Total Current Liabilities | 12.5M +54.11% | 8.1M N/A | |
Total Long-Term Debt | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 45.9M -3.70% | 47.6M N/A | |
Total Liabilities | 58.4M +4.73% | 55.8M N/A | |
Retained Earnings | -259.7M +28.89% | -201.5M N/A | |
Total Stockholders Equity | 98.7M -34.51% | 150.6M N/A | |
Total Shares Outstanding | 22.4M +100,379.82% | 22,300 N/A | |
Cash Flow | |||
Cash from Operating Activities | -46.7M -23.31% | -60.8M N/A | |
Capital Expenditures | 546,000 -78.47% | 2.5M N/A | |
Cash from Investing Activities | 37.8M +244.83% | -26.1M N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 141,000 -99.84% | 89.8M N/A | |
Financials Ratio | |||
Gross Margin | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | |
Return on Assets | -32.02% N/A | N/A N/A | |
Return on Equity | -46.69% N/A | N/A N/A | |
Revenue Growth | N/A N/A | N/A N/A | |
Current Ratio | 8.74 N/A | N/A N/A | |
Cash Ratio | 1.43 N/A | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow